BCL2 and B-cell chronic lymphocytic leukemia: Another study reported that the mTOR inhibitor CC-115 can reverse CD40-mediated resistance of CLL cells to venetoclax, through blocking CD40-induced Mcl-1 and Bcl-xL up-regulation, thus suggesting a role for mTOR in the control of the Bcl-2 family of proteins [12].